A 56-year-old man living in Toronto, Ontario, presented to his family physician after finding a lump in his right breast on self-inspection. He described a onemonth history of pressure and tenderness at the site of the mass. No other lumps were detected, and there was no history of fever, sweats, weight loss or previous trauma to the breast. He had a history of obstructive sleep apnea, took no medications and did not use recreational or injection drugs. The patient had no relevant family history and no contacts with people who were ill. His history of travel was limited to his cottage in central Ontario.
What is the most common cause of a breast mass in a man?
a. Gynecomastia b. Breast carcinoma c. Benign fibrocystic changes d. Inflammatory/infectious diseases of the breast e. Lymphoma Gynecomastia is the most common cause of combined unilateral and bilateral breast mass(es) in men (Box 1). [1] [2] [3] [4] Clinically, gynecomastia usually presents as a concentric retroareolar rubbery mass. 4 This patient's mass was atypical of gynecomastia as it extended medially in an asymmetric fashion. Given the possibility of a malignant cause, the patient was referred for further evaluation to a rapid diagnostic clinic for breast cancer.
At the clinic, the patient received a mammogram, ultrasonography and a core biopsy of the mass. Mammography showed a well-defined 2.5-cm mass located within the right breast (Figure 1) . No calcifications were present. Ultrasonography confirmed these findings and did not detect any substantial regional lymphadenopathy. A core biopsy and tissue staining suggested a fungal cause (Figure 2 and Appendix 1, available at www.cmaj .ca /lookup /suppl /doi :10 .1503 /cmaj .110953/-/DC1.), but no specimen was sent for culture. Based on the results of the biopsy, the patient was referred to an outpatient clinic for infectious diseases for further evaluation and management of the condition.
• Inflammation or infection: 2%-3% of cases
• Other benign diseases of the breast, such as fibrocystic disease, duct papilloma, lipoma or epidermoid cysts: 10%-13% of cases To avoid further invasive testing, a polymerase chain reaction test (amplifying the internal transcribed spacer of the fungal ribosomal DNA using ITS3 and ITS4 primers) was done after digestion and extraction of the paraffin-embedded specimen, and a positive result was found. 8 The amplicon was sequenced, and B. dermatitidis was confirmed. A second biopsy for culture would be a reasonable alternative if polymerase chain reaction testing were not readily available.
Given the limited differential diagnosis of blastomycosis and cryptococcosis, empiric treatment would be less ideal, as the recommended first-line antifungal agents for cryptococcosis and blastomycosis differ, 9,10 and a diagnosis of extrapulmonary cryptococcal infection would raise the issue of whether a lumbar puncture was required to exclude infection of the central nervous system. Clinical monitoring for resolution should not be performed as the patient would be at risk of the disease progressing.
A contrast-enhanced computed tomographic (CT) scan of the thorax was done to determine the extent of tissue invasion and to assess for a primary pulmonary source of infection ( Figure 3 ). The image showed the right breast mass, with no evidence of parenchymal lung disease. Serologic testing for human immunodeficiency virus was negative. The patient was given itraconazole with a planned duration of 6-12 months. At six months follow-up, the mass was no longer detectable by clinical examination. Treatment continued for three months thereafter.
Discussion
Blastomycosis is a pyogranulomatous infection caused by the dimorphic fungus B. dermatitidis. This organism is saprophytic (it derives nourishment from decaying organic matter) and preferentially inhabits moist soils, typically adjacent to waterways. Blastomycosis is predominantly a North American disease, occurring most frequently in regions near bodies of water, such as states adjacent to the Ohio and Mississippi River basins or the states and provinces near the Great Lakes. The route of entry is usually via the lungs, when spores released from soil or decomposing organic matter are inhaled. Rarely, cutaneous inoculation can occur through trauma or animal bites. Disease can occur in both immunocompetent and immunocompromised hosts, although disseminated disease is more common in the latter. 
Epidemiology
Annual North American incidence rates are highest in two hyperendemic regions: Kenora, Ont., (117.2 cases/100 000 population) and Vilas County, Wisconsin 11 (100 cases/100 000 population). In Ontario, the north has the highest annual incidence (2.44 cases/100 000 population), and the Toronto area has the second highest annual incidence (0.26 cases/100 000 population). 11 The central east region of the province has an annual incidence rate of 0.08 cases per 100 000 population. 11 The high incidence rates in Toronto could reflect autochthonous acquisition (primary infection occurring in Toronto) or diagnoses within the Toronto area with acquisition of the fungus elsewhere. It is possible that our patient acquired his infection at either his cottage or at his home.
Clinical features
Patients with blastomycosis can appear along a spectrum of illness from minimally symptomatic, localized disease to fulminant and disseminated presentations. Pulmonary blastomycosis can be acute or chronic, and can present as airspace disease, mass lesions, interstitial lung disease or cavitary disease on radiographic imaging. 5 There is pulmonary involvement in 91.4% of cases of blastomycosis, but other organ systems may also be affected (e.g., the skin [18 12 Cutaneous disease can arise from dissemination from a primary pulmonary focus of infection or, more rarely, through primary cutaneous inoculation. As many as 50% of patients with presumed secondary cutaneous involvement will have no findings on radiographic imaging of the chest. 13 Our patient's presentation could have been the result of an asymptomatic primary pulmonary route of infection with secondary dissemination to the subcutaneous tissues of the breast. Classically, the skin lesions of blastomycosis are verrucous in nature, but they can also be ulcerative or ap pear as subcutaneous nodules. 5 Blastomycosis of the breast has been reported rarely in the literature (fewer than 10 cases reported in the past 50 years). [14] [15] [16] [17] Most cases describe either a primary pulmonary route of infection or an unclear mechanism of infection, as seen in our patient.
Diagnosis
The diagnosis of blastomycosis is usually made by one of three methods: histopathologic examination of tissue specimens, direct microscopy and fungal culture or, less commonly, molecular testing (polymerase chain reaction).
Culture and staining of specimens from the respiratory tract has a sensitivity of 75% for an individual sputum specimen in patients with pulmonary blastomycosis. These methods allow for diagnosis by observation of yeast forms on direct examination and by growth of a mould with typical features of B. dermatitidis. 5, 18 Various types of polymerase chain reaction testing (conventional, real-time or multiplex) can be used to detect and amplify fungal DNA targets, with subsequent confirmation using sequencing or the binding of specific probes. The combination of polymerase chain reaction testing and sequencing assay should be validated for all laboratories using such methods on diagnostic specimens. For our patient, molecular identification avoided the need for further invasive tissue sampling.
Antigen or antibody tests, though available, have limited utility owing to their low specificity secondary to cross reactivity with other fungal species (most commonly H. capsulatum). 5 In regions where histoplasmosis and blastomycosis are not coendemic, these assays may be of greater diagnostic use.
Treatment
Optimal treatment for blastomycosis depends on the site and severity of disease. 9 Reports of expert committees and expert opinion recommend formulations of amphotericin B as a starting point for severe or disseminated disease, including those that involve the central nervous system and in patients with impaired immune function. 9 The success rates of treatment with amphotericin B in moderate to severe disseminated disease range from 70% to 91%. 9 For continuation therapy, and for mild to moderate pulmonary and disseminated disease, itraconazole is the preferred antifungal agent based on nonrandomized clinical studies. 9 The rate of success for treatment of mild to moderate disease with itraconazole approaches 95%. 9 Standard doses of ketoconazole and fluconazole show reduced activity against B. dermatitidis, and voriconazole lacks sufficient evidence to support its first-line use. 5, 9 Echinocandins, such as caspofungin or micafungin, have poor activity against B. dermatitidis and should not be used. 9 For patients such as ours, who have mild extrapulmonary disease, it is recommended that treatment last at least six months; this can be continued for up to one year, depending on the patient's response to therapy. 
Summary
The experience of our patient highlights several important points. First, infectious causes should be considered in the differential diagnosis of subcutaneous masses, including breast masses, and appropriate microbiologic investigations should be requested to confirm diagnoses. Second, blastomycosis, an endemic mycosis in several parts of Canada, can be diagnosed through multiple methods that include the histopathologic examination of tissue specimens, direct microscopy and fungal culture, and molecular-based techniques. For our patient, a molecular-based technique allowed for a definitive diagnosis and avoided repeated invasive tissue sam pling. Finally, itraconazole is an effective treatment for mild to moderate disease in patients who are not substantially immunocompromised.
